Patents by Inventor Irene Bozzoni

Irene Bozzoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • miR-31 in duchenne muscular dystrophy therapy
    Patent number: 9034838
    Abstract: The invention relates to the therapy of Duchenne Muscular Dystrophy (DMD) by means of modulating the amount of a specific miRNA (miR-31).
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: May 19, 2015
    Assignee: UNIVERSITA DEGLI STUDI DI ROMA “LA SAPIENZA”
    Inventors: Irene Bozzoni, Julie Martone, Davide Cacchiarelli, Tania Incitti
  • miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY
    Publication number: 20120129920
    Abstract: The invention relates to the therapy of Duchenne Muscular Dystrophy (DMD) by means of modulating the amount of a specific miRNA (miR-31).
    Type: Application
    Filed: May 24, 2010
    Publication date: May 24, 2012
    Applicant: UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA"
    Inventors: Irene Bozzoni, Julie Martone, Davide Cacchiarelli, Tania Incitti
  • miRNA BIOMARKERS FOR THE DIAGNOSIS OF DUCHENNE MUSCULAR DYSTROPHY, ITS PROGRESSION AND FOR MONITORING THERAPEUTIC INTERVENTIONS
    Publication number: 20120115150
    Abstract: The invention refers to diagnosis and therapy of muscle degenerative disorders, as Duchenne Muscular Dystrophy (DMD) by means of a class of specific miRNAs.
    Type: Application
    Filed: May 24, 2010
    Publication date: May 10, 2012
    Applicant: UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA"
    Inventors: Irene Bozzoni, Julie Martone, Davide Cacchiarelli, Erika Girardi
  • MODIFIED snRNAs FOR USE IN THERAPY
    Publication number: 20110301218
    Abstract: The invention relates to a nucleic acid encoding a small nuclear RNA (snRNA), which snRNA is modified so that it contains sequence capable of hybridizing with the 5? and 3? splice site junctions and an exonic splicing enhancer of an exon of a pre-mRNA, so that the exon sequence is skipped during the splicing process that converts the pre-mRNA in the mature mRNA. The nucleic acid, the modified snRNA and vectors incorporating the nucleic acid may be used in the therapy, in particular in the treatment of muscular dystrophies.
    Type: Application
    Filed: February 11, 2011
    Publication date: December 8, 2011
    Inventors: Irene Bozzoni, Femanda De Angelis, Tania Incitti
  • siRNA expression system
    Patent number: 7947823
    Abstract: The authors describe an expression system for the correct, stable and effective expression in mammalian cells of a siRNA comprising: a) a polymerase II RNA-dependent promoter derived from the U1 RNA gene; downstream from the sequence b) suitable restriction sites for the cloning of the sequence transcribing the pre-siRNA; downstream from these sites c) sequences derived from the sequences at 3? of the gene for U1 snRNA that are necessary and sufficient for the correct formation of 3? of the presiRNA.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: May 24, 2011
    Assignee: Universita degli Studi di Roma “La Sapienza”
    Inventors: Irene Bozzoni, Michela Alessandra Denti, Alessandro Rosa
  • MIRNA, SIRNA AND USE THEREOF IN THERAPY
    Publication number: 20110009468
    Abstract: The present invention relates to a mixture of molecules comprising at least one miRNA and at least one siRNA, or at least two miRNAs, or at least two siRNAs for inducing hematopoietic differentiation or for treating leukemia wherein the miRNA is able to modulate hematopoietic differentiation and/or to act as oncosuppressor, and the siRNA is able to modulate hematopoietic differentiation or to inhibit the expression of a fusion product deriving from a chromosomic translocation associated to leukemia.
    Type: Application
    Filed: November 14, 2008
    Publication date: January 13, 2011
    Applicant: UNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA"
    Inventors: Irene Bozzoni, Alessandro Fatica, Alessandro Rosa
  • Purification, cloning and biochemical characterization of XendoU, endoribonucleasic activity involved in small nuclear RNA splicing-independent biosynthesis in Xenopus laevis
    Patent number: 7459298
    Abstract: Cloning and characterization of the gene for Mn++ dependent RNA-sc endoribonucleasic activity able to generate 2?-3? cyclic phosphate and 5?OH ends.
    Type: Grant
    Filed: July 4, 2003
    Date of Patent: December 2, 2008
    Assignees: Universita'Degli Studi di Roma “La Sapienza”, Consiglio Nazionale Delle Ricerche
    Inventors: Irene Bozzoni, Elisa Caffarelli, Pietro Laneve
  • Sirna expression system
    Publication number: 20060217327
    Abstract: The authors describe an expression system for the correct, stable and effective expression in mammalian cells of a siRNA comprising: a) a polymerase H RNA-dependent promoter derived from the U1 RNA gene; downstream from the sequence b) suitable restriction sites for the cloning of the sequence transcribing the pre-siRNA; downstream from these sites c) sequences derived from the sequences at 3? of the gene for U1 snRNA that are necessary and sufficient for the correct formation of 3? of the presiRNA.
    Type: Application
    Filed: July 9, 2004
    Publication date: September 28, 2006
    Inventors: Irene Bozzoni, Michela Denti
  • Purification, cloning and biochemical characterization of xendou, endoribonucleasic activity involved in small nuclear rna splicing-independent biosynthesis in xenopus laevis
    Publication number: 20060084062
    Abstract: Cloning and characterization of the gene for Mn++ dependent RNA-sc endoribonucleasic activity able to generate 2?-3? cyclic phosphate and 5?OH ends.
    Type: Application
    Filed: July 4, 2003
    Publication date: April 20, 2006
    Inventors: Irene Bozzoni, Elisa Caffarelli, Pietro Laneve
  • Ribozyme-snRNA chimeric molecules having a catalytic activity for nuclear RNAs
    Patent number: 5994124
    Abstract: The invention is drawn to a chimeric ribozyme molecule that comprises a U1 snRNA component and a ribozyme component where the chimeric ribozyme targets an mRNA in the spliceosome in the nuclease of a cell.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: November 30, 1999
    Assignee: Universita' Degli Studi Di Roma 'La Sapienza'
    Inventor: Irene Bozzoni